We previously demonstrated that systemic administration of the specific CXCR4 antagonist AMD 3100, inhibited the intracranial growth of U87 glioblastoma xenografts by increasing apoptosis and decreasing proliferation of tumor cells [14]. This evidence concerns the gene CXCR4 and glioblastoma.